The usual treatment for breast cancer consists of surgery and radiation therapy to slow the progression of the disease in the breast, lymph nodes, and surrounding areas, and systemic therapy to treat and/or reduce the risk of cancer spread. Radiotherapy can be used at almost all stages, and this treatment is an effective way to reduce the risk of recurrence after surgery. However, radiation to the breast can cause acute side effects, reversible in the short term, and delayed side effects, which are essentially in the form of breast fibrosis. For this reason, it is necessary to investigate and develop a reproducible assay that makes it possible to predict the individual radiosensitivity of normal tissues on radiotherapy.

The objective of the project is to develop a multiparametric predictive molecular signature capable of identifying the toxicity derived from radiotherapy in women with breast cancer. The values of different biomarkers and clinical parameters will be compared in a trial cohort, selecting those that make it possible to differentiate patients who develop adverse effects from those who do not, and then a validation cohort will be analysed.